{"product_id":"ebs-bcg-matrix","title":"(EBS) Emergent BioSolutions Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Emergent BioSolutions Inc. BCG Matrix is a company-specific strategy tool used to assess which products or business units fall into Stars, Cash Cows, Question Marks, or Dogs. This page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNARCAN 4 mg OTC naloxone\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNARCAN 4 mg OTC naloxone is Emergent BioSolutions Inc.'s clearest Star: it has strong share in a growing U.S. overdose-prevention market, and over-the-counter access keeps the addressable base wide. The CDC reported 107,543 drug overdose deaths in 2023, so demand for naloxone stays high. Brand leadership matters here, and NARCAN remains the best-known OTC option.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNaloxone nasal spray franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe naloxone nasal spray franchise fits a Star: the 4 mg OTC format sits in a growing harm-reduction market, while pharmacy, public-health, and first-responder channels keep repeat demand high. U.S. overdose deaths were still above 80,000 in recent CDC 12-month data, so access stays urgent. Broad awareness and wide distribution help protect share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpioid overdose reversal market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eU.S. opioid overdose deaths were about 80,391 in the 12 months ended Sep. 2024, so demand for reversal products stays high. Emergent BioSolutions’ NARCAN nasal spray posted $213.3 million in net sales in 2024, and the over-the-counter channel supports repeat purchases. This Star can scale fast because public programs and retail access keep volume recurring. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eConsumer-facing rescue access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOTC NARCAN turned rescue access into a consumer channel, not just an institutional one. The FDA switch in March 2023 widened reach beyond first responders and hospitals, lifting unit demand and keeping the brand visible at retail. For Emergent BioSolutions Inc., this is one of the few spots with both growth and real brand pull.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOTC expands the addressable market.\u003c\/li\u003e\n\u003cli\u003eRetail boosts unit demand and visibility.\u003c\/li\u003e\n\u003cli\u003eNARCAN is a rare brand-strength driver.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic health naloxone channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eState, local, and community programs still push Naloxone at scale, with over 100,000 U.S. overdose deaths a year keeping demand high. For Emergent BioSolutions Inc., these channels support repeat use, broad access, and strong product rotation, so Public health naloxone looks like a Star, not a mature utility product.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-volume public channels sustain demand\u003c\/li\u003e\n\u003cli\u003eOverdose crisis keeps adoption elevated\u003c\/li\u003e\n\u003cli\u003eRepeat access supports franchise growth\u003c\/li\u003e\n\u003cli\u003eStar profile fits active public-health use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNARCAN Powers Emergent’s Growth as Demand Stays High\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNARCAN is Emergent BioSolutions Inc.'s main Star: OTC access widened demand, while the U.S. overdose crisis kept need high. 2024 NARCAN net sales were $213.3 million, and CDC 12-month overdose deaths through Sep. 2024 were about 80,391, so this franchise still has strong growth and brand pull.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNARCAN net sales\u003c\/td\u003e\n\u003ctd\u003e$213.3 million, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. overdose deaths\u003c\/td\u003e\n\u003ctd\u003e80,391, 12 months ended Sep. 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey driver\u003c\/td\u003e\n\u003ctd\u003eOTC access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eEmergent BioSolutions BCG Matrix spots defense-biothreat cash cows, niche question marks, and weaker dogs to invest, hold, or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix for Emergent BioSolutions Inc. to pinpoint business units fast and simplify portfolio decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Emergent BioSolutions Inc., helping users verify key claims fast and make better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioThrax 1 licensed anthrax vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioThrax is Emergent BioSolutions Inc.'s cash cow: it is the only FDA-licensed anthrax vaccine in the U.S. and sells into a mature federal preparedness market with few rivals. That keeps demand steady, pricing resilient, and promotion spend low. In a government-driven niche, BioThrax can keep generating cash even when growth is flat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eACAM2000 1 of 2 U.S. smallpox vaccines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eACAM2000 is one of 2 U.S. smallpox vaccines, so it sits in a mature, low-growth stockpiling market. Its long-running U.S. government role supports steady procurement, and the product’s public-health use keeps demand durable even when volumes do not grow fast. That mix of high share and limited growth makes ACAM2000 a classic cash cow for Emergent BioSolutions Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBAT 7-valent botulism antitoxin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBAT 7-valent botulism antitoxin is a classic Cash Cow for Emergent BioSolutions Inc.: it covers 7 serotypes, serves a narrow public-health niche, and depends on recurring U.S. strategic stockpile demand. The market is small and slow-growing, but preparedness buying keeps it relevant, so the asset can generate steady revenue with limited need for heavy growth spending. In BCG terms, it fits a mature, defense-linked product that supports cash flow more than expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVIGIV smallpox vaccine complication therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVIGIV is a narrow biodefense product used only for vaccinia-related complications after smallpox vaccination, so it does not rely on broad market demand. In 2025, that kind of preparedness-driven need kept it low-growth but useful for cash flow, since government stockpiling matters more than repeat retail use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare, medical-use-only demand\u003c\/li\u003e\n\u003cli\u003eDriven by preparedness spending\u003c\/li\u003e\n\u003cli\u003eLow growth, steady cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRSDL CBRN decontamination kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRSDL decontamination kits fit Emergent BioSolutions Inc. cash-cow slot because they serve CBRN readiness and sell into steady institutional buying, not fast consumer demand. RSDL has been FDA-cleared for military and first-responder use since 2003, so the franchise is mature and keeps generating cash from repeat procurement.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCBRN readiness drives recurring orders\u003c\/li\u003e\n\u003cli\u003eMature product, low growth\u003c\/li\u003e\n\u003cli\u003eInstitutional demand supports cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmergent BioSolutions’ Steady Cash Cows: Biodefense’s Reliable Revenue Engines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEmergent BioSolutions Inc.'s cash cows are mature biodefense assets: BioThrax, ACAM2000, BAT, VIGIV, and RSDL. They serve U.S. stockpile and preparedness demand, so growth is low but cash flow stays steady. In 2025, this mix still fit a classic BCG cash-cow profile: high share, weak growth, and recurring government orders.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eCash-cow cue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioThrax\u003c\/td\u003e\n\u003ctd\u003eOnly FDA-licensed anthrax vaccine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eACAM2000\u003c\/td\u003e\n\u003ctd\u003e1 of 2 U.S. smallpox vaccines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBAT\u003c\/td\u003e\n\u003ctd\u003e7-serotype stockpile product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVIGIV\u003c\/td\u003e\n\u003ctd\u003eNiche post-vaccinia use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRSDL\u003c\/td\u003e\n\u003ctd\u003eRecurring CBRN readiness orders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eEmergent BioSolutions Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Emergent BioSolutions Inc. BCG Matrix you’re previewing is the exact same document you’ll receive after purchase. No hidden changes, no demo content—just the full, ready-to-use report. You’ll get the same professionally formatted file for immediate download, editing, or presentation. What you see here is what you own.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVivotif oral typhoid vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVivotif is a travel vaccine in a narrow, low-growth niche, so it fits Emergent BioSolutions Inc.’s Dogs bucket. Typhoid still causes about 9 million to 14 million cases and 110,000 to 160,000 deaths a year, but the U.S. travel-vaccine market is small and crowded. With limited scale versus larger travel-health brands, Vivotif looks like a stable but weak-share asset. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaxchora single-dose oral cholera vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVaxchora is a single-dose oral vaccine for adults 18 to 64, but cholera prevention is still a narrow travel and outbreak use case. Emergent BioSolutions does not separately disclose Vaxchora sales, which signals a small commercial footprint and limited scale. With low volume and modest growth, it fits a weak BCG position, closer to a question mark than a star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrobigard dual auto-injector\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrobigard dual auto-injector is a niche CBRN countermeasure for nerve-agent emergency use, so demand depends on slow, procurement-led government buying. That kind of market is small and lumpy, which limits share upside and keeps returns tight. In Emergent BioSolutions Inc.'s mix, it fits a Dog: low growth, narrow use case, and limited scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCOVID-HIG SARS-CoV-2 hyperimmune\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCOVID-HIG SARS-CoV-2 hyperimmune sits in the dog quadrant because the COVID-19 treatment market has shrunk hard since the 2020-2022 peak, and demand for passive immunotherapy is now thin. With most spending shifted to vaccination and only sporadic treatment use, the product has weak growth, weak pricing power, and limited pull in 2025-2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket demand has faded sharply.\u003c\/li\u003e\n\u003cli\u003eCommercial pull is now uncertain.\u003c\/li\u003e\n\u003cli\u003eFits a low-growth dog profile.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy CDMO manufacturing footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEmergent BioSolutions Inc.'s legacy CDMO manufacturing footprint fits Dog status: contract manufacturing is crowded, price-sensitive, and low-margin, while the unit has faced restructuring and utilization pressure. In 2025, the company kept cutting costs and narrowing its manufacturing base, which points to weak share in a tough market. That mix usually means limited growth and poor cash use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow pricing power\u003c\/li\u003e\n\u003cli\u003eWeak utilization\u003c\/li\u003e\n\u003cli\u003eRestructuring drag\u003c\/li\u003e\n\u003cli\u003eSmall share, low margin\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmergent’s Dogs: Small Markets, Weak Growth, Limited 2025–2026 Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEmergent BioSolutions Inc.’s Dogs are narrow, low-growth assets with weak scale: Vivotif, Vaxchora, Trobigard, COVID-HIG, and legacy CDMO. Typhoid still brings 9M-14M cases and 110k-160k deaths a year, but these brands sit in small, crowded markets with limited 2025-2026 commercial pull.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVivotif\u003c\/td\u003e\n\u003ctd\u003eLow share\u003c\/td\u003e\n\u003ctd\u003eSmall travel-vaccine niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID-HIG\u003c\/td\u003e\n\u003ctd\u003eWeak demand\u003c\/td\u003e\n\u003ctd\u003eTreatment demand faded in 2025-2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAV7909 anthrax vaccine candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAV7909 is a next-generation anthrax vaccine candidate with clear U.S. biodefense value, since anthrax preparedness stays a federal priority. Its commercial share is still 0 because it is not yet a scaled product. Emergent BioSolutions should keep funding development or secure a partner, because a 2-dose, easier-use profile could move it from Question Mark to Star if government demand converts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAP003 multidose naloxone nasal spray\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAP003 multidose naloxone nasal spray sits in a growing overdose-reversal market, with U.S. overdose deaths still at about 107,543 in the 12 months ended Sep. 2024. It can build on Emergent BioSolutions Inc.'s naloxone franchise, but it has no proven share or sales track record yet. That mix of high upside and unclear traction makes it a classic question mark.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAP007 sustained-release nalmefene injection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAP007 sustained-release nalmefene injection fits the question mark role: it targets opioid use disorder, a market with roughly 80,000 U.S. overdose deaths a year, but its sales are still unproven. For Emergent BioSolutions Inc., that means high need and high upside, but low current share and no clear commercial win yet. If uptake improves, AP007 could move toward a star; if not, it stays a costly bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCHIKV VLP chikungunya vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChikungunya is a high-need market: the WHO estimates about 5.6 billion people live in areas at risk, and outbreaks can spread fast. For Emergent BioSolutions Inc., CHIKV VLP is still a question mark because the market is emerging, but the asset has no commercial scale or proven revenue base yet.\u003c\/p\u003e\n\u003cp\u003eThat means upside is real, but so is execution risk. Until Emergent BioSolutions Inc. converts the program into late-stage data, regulatory progress, and sales, it stays in the question mark box.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh unmet need, large at-risk population.\u003c\/li\u003e\n\u003cli\u003eEmerging market, no scale yet.\u003c\/li\u003e\n\u003cli\u003eHigh upside, high uncertainty.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUniFlu universal influenza vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUniFlu is a Question Mark for Emergent BioSolutions Inc. because it targets a huge flu market, but it still has no sales or market share. Seasonal influenza causes up to 1 billion infections and 290,000-650,000 respiratory deaths a year, so a true universal vaccine could win a multi-billion-dollar market if efficacy and FDA\/EMA milestones land.\u003c\/p\u003e\n\u003cp\u003eFor now, it needs heavy R\u0026amp;D spend and clinical proof before it can move toward Star status, so near-term value is optionality, not cash flow. That means high upside, but also high execution risk and a long path to commercialization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHuge market, zero current share\u003c\/li\u003e\n\u003cli\u003ePipeline asset, not a revenue driver\u003c\/li\u003e\n\u003cli\u003eNeeds funding, data, and approvals\u003c\/li\u003e\n\u003cli\u003eHigh upside if efficacy holds\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmergent’s Question Marks: Big Markets, Unproven Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEmergent BioSolutions Inc.'s Question Marks have big upside but no proven scale yet. AV7909, AP003, AP007, CHIKV VLP, and UniFlu all target urgent unmet needs, but each still lacks meaningful sales or market share. With U.S. overdose deaths at 107,543 in the 12 months ended Sep. 2024 and chikungunya risk near 5.6 billion people, success depends on trial wins, approvals, and adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eWhy it is a Question Mark\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAV7909\u003c\/td\u003e\n\u003ctd\u003eNo scaled share yet\u003c\/td\u003e\n\u003ctd\u003e0 sales base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAP003\u003c\/td\u003e\n\u003ctd\u003eUnproven traction\u003c\/td\u003e\n\u003ctd\u003e107,543 deaths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAP007\u003c\/td\u003e\n\u003ctd\u003eHigh need, no win yet\u003c\/td\u003e\n\u003ctd\u003e80,000 deaths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCHIKV VLP\u003c\/td\u003e\n\u003ctd\u003eEmerging market\u003c\/td\u003e\n\u003ctd\u003e5.6 billion at risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUniFlu\u003c\/td\u003e\n\u003ctd\u003eHuge market, no sales\u003c\/td\u003e\n\u003ctd\u003e1 billion infections\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234358796553,"sku":"ebs-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ebs-bcg-matrix.webp?v=1785717323","url":"https:\/\/dcfanalyst.com\/products\/ebs-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}